Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 11, Number 1—January 2005

Research

Demand for Prophylaxis after Bioterrorism-Related Anthrax Cases, 2001

Edward A. Belongia*Comments to Author , Burney Kieke*, Ruth Lynfield†, Jeffrey P. Davis‡, and Richard E. Besser§
Author affiliations: *Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA; †Minnesota Department of Health, Minneapolis, Minnesota, USA; ‡Wisconsin Division of Public Health, Madison, Wisconsin, USA; §Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Figure 1

A) Actual and predicted fluoroquinolone prescriptions, January 2000 through December 2002. B) Actual and predicted fluoroquinolone prescriptions as a percentage of all outpatient antibiotic prescriptions, January 2000 through December 2002. Tetracycline and related antimicrobial agents were excluded from the denominator in each month. Vertical bars show 95% confidence intervals. All models included categorical effects for year and month and indicator variables for October, November, and December

Figure 1. A) Actual and predicted fluoroquinolone prescriptions, January 2000 through December 2002. B) Actual and predicted fluoroquinolone prescriptions as a percentage of all outpatient antibiotic prescriptions, January 2000 through December 2002. Tetracycline and related antimicrobial agents were excluded from the denominator in each month. Vertical bars show 95% confidence intervals. All models included categorical effects for year and month and indicator variables for October, November, and December, 2001

Main Article

TOP